We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Daily Magnesium-supplement for Severe Asthmatics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01113151
Recruitment Status : Completed
First Posted : April 29, 2010
Last Update Posted : September 4, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to reveal possible beneficial effects of daily magnesium supplement for severe asthmatics, refractory to conventional treatment.

Condition or disease Intervention/treatment
Asthma Dietary Supplement: Mablet (Magnesium-supplement) Other: Placebo

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics
Study Start Date : April 2011
Primary Completion Date : March 2013
Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Magnesium
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
No Intervention: Washout
Active Comparator: Mablet Dietary Supplement: Mablet (Magnesium-supplement)
3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
Other Name: Mablet
Placebo Comparator: Placebo Other: Placebo
3 placebo tablets daily for 12 weeks

Outcome Measures

Primary Outcome Measures :
  1. Asthma control test (ACT) [ Time Frame: Two years ]
    Questionnaire providing a level of disease control

Secondary Outcome Measures :
  1. EQ-5D [ Time Frame: Two years ]
    Questionnaire providing a degree of quality of life

  2. Spirometry [ Time Frame: Two years ]
    Lung function testing

  3. Reversibility testing [ Time Frame: Two years ]
    Lung function reversibility testing with beta2-agonists

  4. Diary [ Time Frame: Two years ]
    Participants will register asthma symptoms, use of reliever medication and exacerbations

  5. Adverse effects [ Time Frame: Two years ]
  6. Blood- and urine samples [ Time Frame: Two years ]
    Se-magnesium, dU-magnesium, se-creatinin, se-potassium, se-sodium, se-albumine, se-Ca2+, se-phosphate, dU-Ca and dU-creatinine

  7. Endogen NO in expiratory breath and Impulse Oscillometry. [ Time Frame: Two years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • severe asthmatics, refractory to conventional treatment, including systemic steroid treatment; symptoms must be annual.

Exclusion Criteria:

  • Se-Mg > 2,00 mmol/L,
  • smoking cessation less than 1 year prior to study start,
  • major changes in eating habits within three months prior to study start and during the study period of approximately one year,
  • various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01113151

Research Dept. of Respiratory Medicine, Aarhus University Hospital
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Gunnar Kjems APS
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Aarhus University Hospital
Principal Investigator: Ronald Dahl, Professor Dept. of Respiratory Medicine, Aarhus University Hospital, Denmark
More Information


Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01113151     History of Changes
Other Study ID Numbers: 9727c
First Posted: April 29, 2010    Key Record Dates
Last Update Posted: September 4, 2013
Last Verified: September 2013

Keywords provided by University of Aarhus:
Severe asthmatics
Annual symptoms
Daily magnesium supplement
ACT (asthma control test)

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases